Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting Insulin

Completed

• Conditions: Type-2 Diabetes Mellitus (T2DM)
• Interventions: Other: No treatment given

• Registration Number: NCT06592950
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

The primary objective of this research is to assess T2DM patient preferences for a once weekly insulin treatment. The study involves a qualitative interview phase and quantitative survey phase with a Discrete Choice Experiment (DCE).

Detailed Description

Not available

Study Timeline

• Study Start: 2023-11-02
• Primary Completion: 2024-04-29
• Study Completion: 2024-04-29
• Status Verified: 2024-09
• Study First Submitted: 2024-09-09
• Study First Submitted QC: 2024-09-09
• Last Update Submitted: 2024-09-09
• Study First Posted: 2024-09-12
• Last Update Posted: 2024-09-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 513

Inclusion Criteria

• Patient is an adult aged 18 years or over
• Patient was diagnosed with type-2 diabetes mellitus (T2DM) greater than or equal to 180 days prior to the day of screening
• Patient is currently prescribed a diabetes treatment (e.g., Metformin/Sus, DPP4i, SGLT2i, GLP-1 RA and/or basal insulin)
• Patient is willing and able to provide written informed consent to participate

For qualitative interviews:

• Patient is a fluent speaker of English and is able to read, write, and fully understand the English language
• Patient is a resident in Canada

For quantitative online survey:

• Patient is a fluent speaker of the local language (English/French/Spanish or Japanese) and is able to read, write and fully understand the local language
• Patient is a resident of either Canada, France, Spain or Japan

Exclusion Criteria

• Patient is currently employing a basal-bolus insulin treatment regimen to manage their diabetes
• Patient is unwilling or unable to comply with the needs of the study or has a physical, behavioural or mental condition that, in the opinion of the recruiter may affect the patient's ability to take part in the study, understand the nature, scope and possible consequences of the study, or the responses they might provide.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Quantitative online survey	No treatment given	Across four markets (Canada, France, Spain and Japan)
Qualitative interviews	No treatment given	Conducted in Canada

Primary Outcome Measures

Name	Time	Method
T2DM patient preferences for a once weekly insulin treatment	Day of interview/survey completion (Day 1)	Pre-defined open-ended questions and Discrete Choice Experiment online survey

Trial Locations

Locations (1)

Novo Nordisk; 🇩🇰 Søborg, Denmark